Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Generation and infusion of multi-antigen-specific T cells to prevent complications early after T-cell depleted allogeneic stem cell transplantation-a phase I/II study.

Roex MCJ, van Balen P, Germeroth L, Hageman L, van Egmond E, Veld SAJ, Hoogstraten C, van Liempt E, Zwaginga JJ, de Wreede LC, Meij P, Vossen ACTM, Danhof S, Einsele H, Schaafsma MR, Veelken H, Halkes CJM, Jedema I, Falkenburg JHF.

Leukemia. 2019 Oct 17. doi: 10.1038/s41375-019-0600-z. [Epub ahead of print]

PMID:
31624377
2.

Impact of alemtuzumab pharmacokinetics on T-cell dynamics, graft-versus-host disease and viral reactivation in patients receiving allogeneic stem cell transplantation with an alemtuzumab-based T-cell-depleted graft.

Loeff FC, van Egmond EHM, Moes DJAR, Wijnands C, Von Dem Borne PA, Veelken H, Falkenburg JHF, Jedema I, Halkes CJM.

Transpl Immunol. 2019 Dec;57:101209. doi: 10.1016/j.trim.2019.06.001. Epub 2019 Jun 14.

3.

To bridge, blossom or boost: that is the question.

Arend SM, Jedema I.

Clin Infect Dis. 2019 May 8. pii: ciz370. doi: 10.1093/cid/ciz370. [Epub ahead of print] No abstract available.

PMID:
31067571
4.

Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.

van der Lee DI, Reijmers RM, Honders MW, Hagedoorn RS, de Jong RC, Kester MG, van der Steen DM, de Ru AH, Kweekel C, Bijen HM, Jedema I, Veelken H, van Veelen PA, Heemskerk MH, Falkenburg JHF, Griffioen M.

J Clin Invest. 2019 Feb 1;129(2):774-785. doi: 10.1172/JCI97482. Epub 2019 Jan 14.

5.

CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II.

van Balen P, van Bergen CAM, van Luxemburg-Heijs SAP, de Klerk W, van Egmond EHM, Veld SAJ, Halkes CJM, Zwaginga JJ, Griffioen M, Jedema I, Falkenburg JHF.

Front Immunol. 2018 Dec 18;9:3016. doi: 10.3389/fimmu.2018.03016. eCollection 2018.

6.

Loss of the GPI-anchor in B-lymphoblastic leukemia by epigenetic downregulation of PIGH expression.

Loeff FC, Rijs K, van Egmond EHM, Zoutman WH, Qiao X, Kroes WGM, Veld SAJ, Griffioen M, Vermeer MH, Neefjes J, Frederik Falkenburg JH, Halkes CJM, Jedema I.

Am J Hematol. 2019 Jan;94(1):93-102. doi: 10.1002/ajh.25337. Epub 2018 Nov 25.

7.

The allogeneic HLA-DP-restricted T-cell repertoire provoked by allogeneic dendritic cells contains T cells that show restricted recognition of hematopoietic cells including primary malignant cells.

Laghmouchi A, Hoogstraten C, van Balen P, Falkenburg JHF, Jedema I.

Haematologica. 2019 Jan;104(1):197-206. doi: 10.3324/haematol.2018.193680. Epub 2018 Sep 20.

8.

Immune surveillance by autoreactive CD4-positive helper T cells is a common phenomenon in patients with acute myeloid leukemia.

Lam TS, van de Meent M, Marijt EWA, Falkenburg JHF, Jedema I.

Eur J Haematol. 2018 Aug 4. doi: 10.1111/ejh.13157. [Epub ahead of print]

PMID:
30076646
9.

CMV seronegative donors: Effect on clinical severity of CMV infection and reconstitution of CMV-specific immunity.

van der Heiden PLJ, van Egmond HM, Veld SAJ, van de Meent M, Eefting M, de Wreede LC, Halkes CJM, Falkenburg JHF, Marijt WAF, Jedema I.

Transpl Immunol. 2018 Aug;49:54-58. doi: 10.1016/j.trim.2018.04.003. Epub 2018 Apr 18.

PMID:
29679650
10.

Control of Cytomegalovirus Viremia after Allogeneic Stem Cell Transplantation: A Review on CMV-Specific T Cell Reconstitution.

van der Heiden P, Marijt E, Falkenburg F, Jedema I.

Biol Blood Marrow Transplant. 2018 Sep;24(9):1776-1782. doi: 10.1016/j.bbmt.2018.03.028. Epub 2018 Apr 4. Review.

11.

Tissue Damage Caused by Myeloablative, but Not Non-Myeloablative, Conditioning before Allogeneic Stem Cell Transplantation Results in Dermal Macrophage Recruitment without Active T-Cell Interaction.

van Balen P, van der Zouwen B, Kruisselbrink AB, Eefting M, Szuhai K, Jordanova ES, Falkenburg JHF, Jedema I.

Front Immunol. 2018 Feb 27;9:331. doi: 10.3389/fimmu.2018.00331. eCollection 2018.

12.

The simultaneous isolation of multiple high and low frequent T-cell populations from donor peripheral blood mononuclear cells using the major histocompatibility complex I-Streptamer isolation technology.

Roex MCJ, Hageman L, Heemskerk MT, Veld SAJ, van Liempt E, Kester MGD, Germeroth L, Stemberger C, Falkenburg JHF, Jedema I.

Cytotherapy. 2018 Apr;20(4):543-555. doi: 10.1016/j.jcyt.2018.01.008. Epub 2018 Feb 12.

PMID:
29449085
13.

High Mutation Frequency of the PIGA Gene in T Cells Results in Reconstitution of GPI Anchor-/CD52- T Cells That Can Give Early Immune Protection after Alemtuzumab-Based T Cell-Depleted Allogeneic Stem Cell Transplantation.

Loeff FC, Falkenburg JHF, Hageman L, Huisman W, Veld SAJ, van Egmond HME, van de Meent M, von dem Borne PA, Veelken H, Halkes CJM, Jedema I.

J Immunol. 2018 Mar 15;200(6):2199-2208. doi: 10.4049/jimmunol.1701018. Epub 2018 Feb 2.

14.

Graft versus tumor effects and why people relapse.

Falkenburg JHF, Jedema I.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):693-698. doi: 10.1182/asheducation-2017.1.693. Review.

15.

Mismatched HLA-DRB3 Can Induce a Potent Immune Response After HLA 10/10 Matched Stem Cell Transplantation.

van Balen P, van Luxemburg-Heijs SAP, van de Meent M, van Bergen CAM, Halkes CJM, Jedema I, Falkenburg JHF.

Transplantation. 2017 Dec;101(12):2850-2854. doi: 10.1097/TP.0000000000001713.

PMID:
28252558
16.

Complement-dependent cytotoxicity induced by therapeutic antibodies in B-cell acute lymphoblastic leukemia is dictated by target antigen expression levels and augmented by loss of membrane-bound complement inhibitors.

Loeff FC, van Egmond HME, Nijmeijer BA, Falkenburg JHF, Halkes CJ, Jedema I.

Leuk Lymphoma. 2017 Sep;58(9):1-14. doi: 10.1080/10428194.2017.1281411. Epub 2017 Jan 31.

PMID:
28140725
17.

Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response.

van Bergen CA, van Luxemburg-Heijs SA, de Wreede LC, Eefting M, von dem Borne PA, van Balen P, Heemskerk MH, Mulder A, Claas FH, Navarrete MA, Honders WM, Rutten CE, Veelken H, Jedema I, Halkes CJ, Griffioen M, Falkenburg JH.

J Clin Invest. 2017 Feb 1;127(2):517-529. doi: 10.1172/JCI86175. Epub 2017 Jan 9.

18.

Allo-reactive T cells for the treatment of hematological malignancies.

Falkenburg JH, Jedema I.

Mol Oncol. 2015 Dec;9(10):1894-903. doi: 10.1016/j.molonc.2015.10.014. Epub 2015 Oct 24. Review.

19.

BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells.

Alford SE, Kothari A, Loeff FC, Eichhorn JM, Sakurikar N, Goselink HM, Saylors RL, Jedema I, Falkenburg JH, Chambers TC.

Cancer Res. 2015 Apr 1;75(7):1366-75. doi: 10.1158/0008-5472.CAN-14-1849. Epub 2015 Feb 3.

20.

Monocyte-derived dendritic cells can induce autoreactive CD4(+) T cells showing myeloid lineage directed reactivity in healthy individuals.

Lam TS, van de Meent M, Falkenburg JF, Jedema I.

Eur J Immunol. 2015 Apr;45(4):1030-42. doi: 10.1002/eji.201444819. Epub 2015 Jan 21.

21.

Mutation in PIGA results in a CD52-negative escape variant in a S├ęzary syndrome patient during alemtuzumab treatment.

Halkes CJM, Zoutman WH, van der Fits L, Jedema I, Vermeer MH.

J Invest Dermatol. 2015 Apr;135(4):1199-1202. doi: 10.1038/jid.2014.501. Epub 2014 Nov 28. No abstract available.

22.

Collateral damage of nonhematopoietic tissue by hematopoiesis-specific T cells results in graft-versus-host disease during an ongoing profound graft-versus-leukemia reaction.

van der Zouwen B, Kruisselbrink AB, Frederik Falkenburg JH, Jedema I.

Biol Blood Marrow Transplant. 2014 Jun;20(6):760-9. doi: 10.1016/j.bbmt.2014.03.002. Epub 2014 Mar 7.

23.

A Good Manufacturing Practice procedure to engineer donor virus-specific T cells into potent anti-leukemic effector cells.

van Loenen MM, de Boer R, van Liempt E, Meij P, Jedema I, Falkenburg JH, Heemskerk MH.

Haematologica. 2014 Apr;99(4):759-68. doi: 10.3324/haematol.2013.093690. Epub 2013 Dec 13.

24.

Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report and review of the literature.

Verkaik NJ, Hoek RA, van Bergeijk H, van Hal PT, Schipper ME, Pas SD, Beersma MF, Boucher CA, Jedema I, Falkenburg F, Hoogsteden HC, van den Blink B, Murk JL.

Transpl Infect Dis. 2013 Dec;15(6):E243-9. doi: 10.1111/tid.12156. Epub 2013 Oct 23. Review.

PMID:
24298985
25.

HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD4+ donor lymphocyte infusion.

Stevanovic S, van Bergen CA, van Luxemburg-Heijs SA, van der Zouwen B, Jordanova ES, Kruisselbrink AB, van de Meent M, Harskamp JC, Claas FH, Marijt EW, Zwaginga JJ, Halkes CJ, Jedema I, Griffioen M, Falkenburg JH.

Blood. 2013 Sep 12;122(11):1963-73. doi: 10.1182/blood-2012-12-470872. Epub 2013 Jun 18.

PMID:
23777765
26.

Effective treatment of refractory CMV reactivation after allogeneic stem cell transplantation with in vitro-generated CMV pp65-specific CD8+ T-cell lines.

Meij P, Jedema I, Zandvliet ML, van der Heiden PL, van de Meent M, van Egmond HM, van Liempt E, Hoogstraten C, Kruithof S, Veld S, Marijt EW, von dem Borne PA, Lankester AC, Halkes CJ, Falkenburg JH.

J Immunother. 2012 Oct;35(8):621-8.

PMID:
22996368
27.

Alloreactive effector T cells require the local formation of a proinflammatory environment to allow crosstalk and high avidity interaction with nonhematopoietic tissues to induce GVHD reactivity.

van der Zouwen B, Kruisselbrink AB, Jordanova ES, Rutten CE, von dem Borne PA, Falkenburg JH, Jedema I.

Biol Blood Marrow Transplant. 2012 Sep;18(9):1353-67. doi: 10.1016/j.bbmt.2012.06.017. Epub 2012 Jul 11.

28.

Generation and administration of HA-1-specific T-cell lines for the treatment of patients with relapsed leukemia after allogeneic stem cell transplantation: a pilot study.

Meij P, Jedema I, van der Hoorn MA, Bongaerts R, Cox L, Wafelman AR, Marijt EW, Willemze R, Falkenburg JH.

Haematologica. 2012 Aug;97(8):1205-8. doi: 10.3324/haematol.2011.053371. Epub 2012 Apr 17.

29.

Allogeneic HLA-A*02-restricted WT1-specific T cells from mismatched donors are highly reactive but show off-target promiscuity.

Falkenburg WJ, Melenhorst JJ, van de Meent M, Kester MG, Hombrink P, Heemskerk MH, Hagedoorn RS, Gostick E, Price DA, Falkenburg JH, Barrett AJ, Jedema I.

J Immunol. 2011 Sep 1;187(5):2824-33. doi: 10.4049/jimmunol.1100852. Epub 2011 Aug 5.

30.

PRAME-specific Allo-HLA-restricted T cells with potent antitumor reactivity useful for therapeutic T-cell receptor gene transfer.

Amir AL, van der Steen DM, van Loenen MM, Hagedoorn RS, de Boer R, Kester MD, de Ru AH, Lugthart GJ, van Kooten C, Hiemstra PS, Jedema I, Griffioen M, van Veelen PA, Falkenburg JH, Heemskerk MH.

Clin Cancer Res. 2011 Sep 1;17(17):5615-25. doi: 10.1158/1078-0432.CCR-11-1066. Epub 2011 Jul 19.

31.

Successful generation of primary virus-specific and anti-tumor T-cell responses from the naive donor T-cell repertoire is determined by the balance between antigen-specific precursor T cells and regulatory T cells.

Jedema I, van de Meent M, Pots J, Kester MG, van der Beek MT, Falkenburg JH.

Haematologica. 2011 Aug;96(8):1204-12. doi: 10.3324/haematol.2010.039099. Epub 2011 May 5.

32.

Simultaneous isolation of CD8(+) and CD4(+) T cells specific for multiple viruses for broad antiviral immune reconstitution after allogeneic stem cell transplantation.

Zandvliet ML, van Liempt E, Jedema I, Kruithof S, Kester MG, Guchelaar HJ, Falkenburg JH, Meij P.

J Immunother. 2011 Apr;34(3):307-19. doi: 10.1097/CJI.0b013e318213cb90.

PMID:
21389867
33.

Co-ordinated isolation of CD8(+) and CD4(+) T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy.

Zandvliet ML, van Liempt E, Jedema I, Veltrop-Duits LA, Willemze R, Guchelaar HJ, Falkenburg JH, Meij P.

Cytotherapy. 2010 Nov;12(7):933-44. doi: 10.3109/14653240903505822.

PMID:
20078388
34.

Detailed analysis of IFNg response upon activation permits efficient isolation of cytomegalovirus-specific CD8+ T cells for adoptive immunotherapy.

Zandvliet ML, Falkenburg JH, Jedema I, Willemze R, Guchelaar HJ, Meij P.

J Immunother. 2009 Jun;32(5):513-23. doi: 10.1097/CJI.0b013e3181a2712c.

PMID:
19609244
35.

Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1-reactive cytotoxic T cells.

Norde WJ, Overes IM, Maas F, Fredrix H, Vos JC, Kester MG, van der Voort R, Jedema I, Falkenburg JH, Schattenberg AV, de Witte TM, Dolstra H.

Blood. 2009 Mar 5;113(10):2312-23. doi: 10.1182/blood-2008-04-153825. Epub 2008 Dec 12.

PMID:
19074734
36.

HLA-DP as specific target for cellular immunotherapy in HLA class II-expressing B-cell leukemia.

Rutten CE, van Luxemburg-Heijs SA, Griffioen M, Marijt EW, Jedema I, Heemskerk MH, Posthuma EF, Willemze R, Falkenburg JH.

Leukemia. 2008 Jul;22(7):1387-94. doi: 10.1038/leu.2008.90. Epub 2008 Apr 17.

PMID:
18418406
37.

Characterization of graft-versus-leukemia responses in patients treated for advanced chronic lymphocytic leukemia with donor lymphocyte infusions after in vitro T-cell depleted allogeneic stem cell transplantation following reduced-intensity conditioning.

Hoogendoorn M, Jedema I, Barge RM, van Luxemburg-Heijs SA, Beaumont F, Marijt EW, Willemze R, Falkenburg JH.

Leukemia. 2007 Dec;21(12):2569-74. Epub 2007 Jul 5. No abstract available.

PMID:
17611558
38.

Early detection and rapid isolation of leukemia-reactive donor T cells for adoptive transfer using the IFN-gamma secretion assay.

Jedema I, Meij P, Steeneveld E, Hoogendoorn M, Nijmeijer BA, van de Meent M, van Luxemburg-Heijs SA, Willemze R, Falkenburg JH.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):636-43.

39.

Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene.

van Bergen CA, Kester MG, Jedema I, Heemskerk MH, van Luxemburg-Heijs SA, Kloosterboer FM, Marijt WA, de Ru AH, Schaafsma MR, Willemze R, van Veelen PA, Falkenburg JH.

Blood. 2007 May 1;109(9):4089-96. Epub 2007 Jan 18.

PMID:
17234742
40.

Involvement of caspase-8 in chemotherapy-induced apoptosis of patient derived leukemia cell lines independent of the death receptor pathway and downstream from mitochondria.

de Vries JF, Wammes LJ, Jedema I, van Dreunen L, Nijmeijer BA, Heemskerk MH, Willemze R, Falkenburg JH, Barge RM.

Apoptosis. 2007 Jan;12(1):181-93.

PMID:
17136321
41.

Molecular persistence of chronic myeloid leukemia caused by donor T cells specific for lineage-restricted maturation antigens not recognizing immature progenitor-cells.

von dem Borne PA, van Luxemburg-Heijs SA, Heemskerk MH, Jedema I, Mulder A, Willemze R, Falkenburg JH.

Leukemia. 2006 Jun;20(6):1040-6.

PMID:
16525495
42.

Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer.

Slager EH, Honders MW, van der Meijden ED, van Luxemburg-Heijs SA, Kloosterboer FM, Kester MG, Jedema I, Marijt WA, Schaafsma MR, Willemze R, Falkenburg JH.

Blood. 2006 Jun 15;107(12):4954-60. Epub 2006 Feb 23.

PMID:
16497972
43.

Efficacy and toxicity of gemtuzumab ozogamicin in patients with acute myeloid leukemia.

van der Heiden PL, Jedema I, Willemze R, Barge RM.

Eur J Haematol. 2006 May;76(5):409-13. Epub 2006 Feb 15.

PMID:
16480432
44.

Primary allogeneic T-cell responses against mantle cell lymphoma antigen-presenting cells for adoptive immunotherapy after stem cell transplantation.

Hoogendoorn M, Olde Wolbers J, Smit WM, Schaafsma MR, Jedema I, Barge RM, Willemze R, Falkenburg JH.

Clin Cancer Res. 2005 Jul 15;11(14):5310-8.

46.

High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients.

van der Velden VH, Boeckx N, Jedema I, te Marvelde JG, Hoogeveen PG, Boogaerts M, van Dongen JJ.

Leukemia. 2004 May;18(5):983-8.

PMID:
15029214
47.

New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population.

Jedema I, van der Werff NM, Barge RM, Willemze R, Falkenburg JH.

Blood. 2004 Apr 1;103(7):2677-82. Epub 2003 Nov 20.

PMID:
14630824
48.

Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity.

Jedema I, Barge RM, van der Velden VH, Nijmeijer BA, van Dongen JJ, Willemze R, Falkenburg JH.

Leukemia. 2004 Feb;18(2):316-25.

PMID:
14614514
49.

Recruitment of leukemic cells from G0 phase of the cell cycle by interferons results in conversion of resistance to daunorubicin.

Jedema I, Barge RM, Nijmeijer BA, Willemze R, Falkenburg JH.

Leukemia. 2003 Oct;17(10):2049-51. No abstract available.

PMID:
14513057
50.

Supplemental Content

Loading ...
Support Center